Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effect of Supervised Physical Exercise on Endothelial Function and Endothelial Progenitor Cells in Patients With Systemic Lupus Erythematosus
Brief Summary: The purpose of this study is to evaluate the effect of supervised physical exercise on endothelial function and number of endothelial progenitor cells (EPCs) in patients with systemic lupus erythematosus, as well as evaluate the effect of supervised physical exercise on endothelium derived growth factor (VEGF) levels, disease activity, quality of life, fatigue, perceived exertion and cardiopulmonary exercise test variables.


Options:
A: Inclusion Criteria:

* Positive ANA-titer (≥ 1:80) or Anti-dsDNA (≥ 200 IU/ml) or Highly avid-dsDNA autoantibody (≥ 30 IU/ml)
* Stable immunosuppressive therapy more than 30 days before beginning of the study with steroid (0-20 mg/day) or other immunosuppressive medication like Hydroxchloroquin, Chloroquin, Azathioprin, Methotrexat, Mycophenolatmofetil, Cyclosporin, Belimumab, Rituximab

Exclusion Criteria:

* Pregnancy, Active lupus nephritits, Physical activity more than two times a week
B: Inclusion Criteria:

* Age between 7 and 40 years
* SLEDAI ≤ 4

Exclusion Criteria:

* Cardiovascular dysfunction
* Rhythm and conduction disorders
* Musculoskeletal disturbances
* Kidney and pulmonary involvements
* Peripheral neuropathy
* Use of tobacco
* Treatment with lipid-lowering or hypoglycemic drugs
* Fibromyalgia
* Use of chronotropic or antihypertensive drugs
* Physically active subjects
C: Inclusion Criteria:

* female systemic lupus erythematosus patients
* 18 to 45 years of age
* Fulfilled at least four criteria classification for lupus (ACR criteria, 1997) - Signed the consent form approved by the ethics committee of the institution

Exclusion Criteria:

* Hemoglobin \< 10 mg/dL
* Neuropsychiatric, pulmonary, articular or vascular damage that would prevent the practice of exercise
* Coronary disease or heart failure, functional class ≥ II
* Pulmonary hypertension
* Uncontrolled hypertension
* Creatinine ≥ 1.4 mg/dL
* Body mass index (BMI) ≥ 35 kg/m2
* Diabetes mellitus
* Uncontrolled hypothyroidism
* Smoking in the last 12 months
* Pregnancy
* Menopause
* Use of statins in the last three months
* Practice of physical exercise in past three months
* Overlap with other autoimmune rheumatic diseases, except antiphospholipid syndrome.
D: Primary Inclusion Criteria

* Clinical diagnosis of SLE
* "Active" SLE disease
* On a stable SLE treatment regimen
* History of measurable autoantibodies

Primary Exclusion Criteria

* Received a non-FDA approved investigational agent within last 28 days
* Cyclosporin, intravenous immunoglobulin (IVIG) or plasmapheresis within last 90 days
* Active lupus nephritis requiring hemodialysis, cyclophosphamide (Cytoxan™), or high-dose prednisone (\> 100 mg/day) within last 90 days
* Active central nervous system (CNS) lupus requiring therapeutic intervention within last 60 days
* History of renal transplant
* History of chronic infection that has been active within last 6 months, herpes zoster within last 90 days or any infection requiring hospitalization or intravenous medication within last 60 days
* History of hypogammaglobulinemia or immunoglobulin A (IgA) deficiency
* Human immunodeficiency virus (HIV), Hepatitis B, Hepatitis C

Answer: C